Earnings summaries and quarterly performance for HARVARD BIOSCIENCE.
Executive leadership at HARVARD BIOSCIENCE.
Board of directors at HARVARD BIOSCIENCE.
Research analysts who have asked questions during HARVARD BIOSCIENCE earnings calls.
Recent press releases and 8-K filings for HBIO.
Harvard Bioscience Announces Strategic Manufacturing Consolidation
HBIO
New Projects/Investments
Layoffs
- Harvard Bioscience, Inc. announced a strategic consolidation of its manufacturing operations to enhance efficiency and support long-term growth, which includes the phased closure of its Holliston, MA plant.
- U.S. production will transition to the company's manufacturing hub in Minneapolis, MN, while certain operations will relocate to facilities in Germany, Sweden, and the UK.
- This initiative is expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028.
- The company anticipates incurring pre-tax restructuring charges ranging from approximately $3.4 to $4.4 million, including non-cash asset write-off and/or accelerated depreciation charges of about $0.6 to $0.7 million.
- The Holliston facility will remain operational throughout 2026, with the consolidation expected to be completed by the first quarter of 2027.
Jan 29, 2026, 9:30 PM
Harvard Bioscience Announces Manufacturing Operations Consolidation
HBIO
New Projects/Investments
Cost Savings
- Harvard Bioscience (HBIO) announced a strategic consolidation of its manufacturing operations, which includes closing its Holliston, MA facility and transitioning U.S. production to Minneapolis, MN, with some operations relocating to Germany, Sweden, and the UK.
- The consolidation is expected to be completed by the first quarter of 2027, with the Holliston facility remaining operational throughout 2026 to support continuity.
- This initiative is projected to generate approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028.
- The company anticipates incremental operating expenses related to the transition throughout 2026 and in the first half of 2027.
Jan 29, 2026, 9:30 PM
HARVARD BIOSCIENCE INC Furnishes Investor Update with Q3 2025 Results and 2025 Goals
HBIO
Earnings
Guidance Update
Product Launch
- Harvard Bioscience, Inc. (HBIO) furnished an Investor Update on January 12, 2026, detailing its business strategy and outlook.
- For Q3 2025, the company reported revenue of $20.6 million, which was at the high end of its guidance range, and Adjusted EBITDA of $2 million, an increase from $1.3 million in Q3 2024.
- The gross margin expanded to 58.4% in Q3 2025, exceeding guidance due to disciplined execution, operational efficiency, and an improved mix towards higher-margin products.
- Key priorities for 2025 include maintaining financial discipline, accelerating product adoption across core growth platforms, and strengthening the capital structure through a successful debt refinancing.
- HBIO emphasized its position as a leading global tools provider with a diversified customer base and a strong new product introduction pipeline, including the breakthrough MeshMEA organoid platform.
Jan 12, 2026, 12:30 PM
Harvard Bioscience Announces Debt Refinancing with BroadOak Capital Partners
HBIO
Debt Issuance
Board Change
Convertible Preferred Issuance
- Harvard Bioscience (HBIO) announced the successful completion of a $40 million debt refinancing with BroadOak Capital Partners, which will be used to retire existing debt obligations and strengthen its balance sheet.
- The new credit facility comprises Term Loan A ($10.0 million), Term Loan B ($22.5 million), and a convertible Term Loan C ($7.5 million), all maturing on December 17, 2029.
- The Term C Loan is a senior secured convertible term loan, convertible into common stock at $1.00 per share at BroadOak's option or automatically upon certain conditions.
- The loans will bear interest at a per annum rate equal to the greater of 12.80% (for the first two years) or the prime rate plus 5.25%.
- In connection with the transaction, BroadOak received warrants to purchase 2 million shares at $0.50 per share, and its partner, Bill Snider, joined HBIO's board of directors.
Dec 17, 2025, 12:30 PM
Harvard Bioscience Completes Debt Refinancing and Board Update
HBIO
Debt Issuance
Board Change
New Projects/Investments
- Harvard Bioscience secured a $40 million credit facility from BroadOak Capital Partners, which will be used to retire existing debt obligations and strengthen its balance sheet and capital structure.
- The credit facility, funded on December 17, 2025, includes three senior secured term loans that mature on December 17, 2029.
- As part of the agreement, BroadOak received warrants to purchase 2 million shares of the Company's common stock at $0.50 per share, and BroadOak Partner Bill Snider joined Harvard Bioscience's board of directors.
- The company will also establish a Product, Operations, and Scientific Advisory Board.
Dec 17, 2025, 12:30 PM
Harvard Bioscience Reports Strong Q3 2025 Results and Positive Q4 Outlook
HBIO
Earnings
Guidance Update
Debt Issuance
- Harvard Bioscience reported Q3 2025 revenue of $20.6 million, at the high end of its guidance range, with a gross margin of 58.4% and adjusted EBITDA of $2 million.
- The company generated positive operating cash flow in Q3 2025, contributing to a year-to-date total of $6.8 million, and reduced net debt by over $6 million from year-end 2024 to $27.5 million.
- HBIO's backlog has reached its highest level in nearly two years, and the company expects continued momentum, guiding Q4 2025 revenue to $22.5 million-$24.5 million and gross margin to 58%-60%. The debt refinancing process is also on track for completion in Q4.
Nov 6, 2025, 1:00 PM
HBIO announces Q3 2025 results and Q4 2025 outlook
HBIO
Earnings
Guidance Update
Debt Issuance
- HBIO reported Q3 2025 revenue of $20.6 million, which was at the high end of its guidance range, and a gross margin of 58.4%, exceeding its guidance.
- Adjusted EBITDA for Q3 2025 increased to $2.0 million from $1.3 million in Q3 2024, with cash provided by operations of $6.8 million.
- The company is actively working to refinance or repay its existing credit agreement in the fourth quarter of 2025 to strengthen its capital structure.
- For Q4 2025, HBIO projects revenues between $22.5 million and $24.5 million and a gross margin ranging from 58% to 60%.
Nov 6, 2025, 1:00 PM
Harvard Bioscience Announces Third Quarter 2025 Financial Results
HBIO
Earnings
Guidance Update
Debt Issuance
- Harvard Bioscience reported Q3 2025 revenues of $20.6 million and a gross margin of 58.4%.
- The company posted a net loss of ($1.2) million for Q3 2025, while generating $1.1 million in cash from operations and $2.0 million in Adjusted EBITDA.
- For the nine months ended September 30, 2025, the net loss was ($53.8) million, significantly impacted by a $48.0 million goodwill impairment in the first quarter.
- The company expects to refinance or repay its existing credit agreement in the fourth quarter of 2025.
- Harvard Bioscience provided Q4 2025 revenue guidance of $22.5 million to $24.5 million and expects a gross margin in the 58% to 60% range.
Nov 6, 2025, 12:00 PM
Harvard Bioscience Announces Third Quarter 2025 Financial Results and Q4 2025 Guidance
HBIO
Earnings
Guidance Update
Debt Issuance
- Harvard Bioscience reported Q3 2025 revenues of $20.6 million and a gross margin of 58.4%, generating $1.1 million in cash from operations.
- For the nine months ended September 30, 2025, the company recorded a net loss of ($53.8) million, primarily due to a $48.0 million goodwill impairment in Q1 2025.
- The company provided Q4 2025 revenue guidance of $22.5 million to $24.5 million and a gross margin range of 58% to 60%.
- Harvard Bioscience expects to refinance or repay its existing credit agreement in the fourth quarter of 2025.
Nov 6, 2025, 12:00 PM
Quarterly earnings call transcripts for HARVARD BIOSCIENCE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more